NicOx SA, which is seeking to build an eye-care business after its non-steroidal anti-inflammatory drug for osteoarthritis failed to get regulatory approval, had a profit in the first 2012 quarter due to a milestone from its ophthalmology platform. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
